research Abstract 2205: KRTAP 2-3 is a novel potential biomarker of cells in the polyaneuploid cancer cell (PACC) state to predict cancer recurrence
KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.
Search
for
Sort by
Research
900-930 / 1000+ results research Optical Coherent Tomography for in vivo Determination of Changes in Hair Cross Section and Diameter during Treatment with Glucocorticosteroids – A Simple Method to Screen for Doping Substances?
Optical coherent tomography can effectively detect steroid use by analyzing hair changes.
research Maculopapular rash upon antibiotic therapy in a patient with rheumatoid arthritis
Methotrexate caused a rare skin rash in a rheumatoid arthritis patient, which resolved after stopping the drug.
research Cyproterone Acetate Quantification in Human Plasma by High-performance Liquid Chromatography Coupled to Atmospheric Pressure Photoionization Tandem Mass Spectrometry
The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.
research [[Translated article]]RF- Mesotherapy with Bicalutamide: A Novel Alternative for Androgenetic Alopecia
RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
research Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies
research The Use of New Hematological Markers in the Diagnosis of Alopecia Areata
Certain blood markers, especially MLR, can help diagnose alopecia areata.
research Treatment of invasive aspergillosis with itraconazole
Itraconazole is potentially effective for treating invasive aspergillosis, but more research is needed.
research Broad laboratory testing does not show utility for telogen effluvium: a retrospective analysis of 22-million laboratory results using TriNetX
research Medulla loss of scalp hair in breast cancer patients determined by near-infrared microscopy
Medulla loss in scalp hair could help detect breast cancer.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Simultaneous Estimation of Finateride and Tamsulosin Hydrochloride in Pharmaceutical Dosage forms by Uv Spectrophotometric, RP-HPLC and HPTLC Methods.
Three reliable methods were developed to measure Finasteride and Tamsulosin Hydrochloride in medicines.
research Measurement of cortisol in human Hair as a biomarker of systemic exposure
Hair cortisol can be used to measure long-term stress exposure.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research Confocal microscopy and optical coherence tomography of inflammatory skin diseases in hairs and pilosebaceous units: A systematic review
RCM and OCT are effective for diagnosing and monitoring hair-related skin diseases but lack standardized protocols and need more research.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
research Determination of finasteride in human plasma by HPLC-MS
The method reliably measures finasteride in human plasma.
research Anti-CD44-mediated blockade of leukocyte migration in skin-associated immune diseases
Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.
research Sequential immunotherapy for alopecia areata: phase-driven immune rebalancing
Sequential immunotherapy can effectively treat alopecia areata by managing inflammation and promoting hair regrowth.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab can cause skin issues, but baricitinib may help improve them.
research LB789 Novel IFNγ aptamer TAGX-0003 protected hair follicles from immune privilege collapse and reversed Alopecia Areata like phenotype in humanized mouse model
TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
research Acellular dermal matrix hydrogels promote healing of radiation-induced skin injury in a rat model
ADM hydrogels help heal radiation skin injuries.
research Detection of hair-microRNAs as the novel potent biomarker: Evaluation of the usefulness for the diagnosis of scleroderma
Hair microRNAs could be effective biomarkers for diagnosing scleroderma.
research Evaluation of some biochemical markers in alopecia areata
People with alopecia areata have different blood markers that suggest inflammation and immune system issues compared to healthy individuals.
research Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.
research Normalized androgen ratio: its application to clinical dermatology
The normalized androgen ratio can help manage conditions with excess androgen activity in women.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.